A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

Last Updated   February 22, 2025

Want to learn how to participate in this trial?

74765340RPG2001

OVERVIEW

  • Sexes Eligible for Study
    male
  • Age
    5+ years
  • Phase
    phase 2
    2
  • Sites
    1 Sites
  • Status
     Recruiting

SUMMARY

The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.

CONDITIONS

  • X-Linked Retinitis Pigmentosa

ELIGIBILITY


Inclusion Criteria:

* Have been treated with AAV5-hRKp.RPGR in study MGT009 and have completed or is currently enrolled in Study MGT010
* Must sign an informed consent form indicating that they understand the purpose and procedures of the study and is willing to participate in th

More...

DETAILS

LOCATIONS

Locations in:
United States
Country (1) City or Province (1) Status
United States Ann Arbor University of Michigan Kellogg Eye Center
RECRUITING
Show More
Geo Locations

42.27756, -83.74088

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?